Omega Fund Management LLC lowered its holdings in shares of FibroGen Inc (NASDAQ:FGEN) by 58.4% in the 4th quarter, HoldingsChannel reports. The firm owned 130,646 shares of the biopharmaceutical company’s stock after selling 183,702 shares during the period. FibroGen comprises approximately 4.5% of Omega Fund Management LLC’s portfolio, making the stock its 7th biggest holding. Omega Fund Management LLC’s holdings in FibroGen were worth $6,193,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in FGEN. Wells Fargo & Company MN grew its position in shares of FibroGen by 10.0% during the second quarter. Wells Fargo & Company MN now owns 68,229 shares of the biopharmaceutical company’s stock worth $2,203,000 after purchasing an additional 6,192 shares in the last quarter. BlackRock Inc. boosted its stake in FibroGen by 12.3% during the second quarter. BlackRock Inc. now owns 5,001,406 shares of the biopharmaceutical company’s stock valued at $161,545,000 after buying an additional 546,587 shares during the last quarter. Amalgamated Bank bought a new position in FibroGen during the second quarter valued at approximately $237,000. New York State Common Retirement Fund boosted its stake in FibroGen by 24.0% during the second quarter. New York State Common Retirement Fund now owns 67,700 shares of the biopharmaceutical company’s stock valued at $2,187,000 after buying an additional 13,099 shares during the last quarter. Finally, Northern Trust Corp boosted its stake in FibroGen by 14.4% during the second quarter. Northern Trust Corp now owns 734,483 shares of the biopharmaceutical company’s stock valued at $23,724,000 after buying an additional 92,483 shares during the last quarter. Hedge funds and other institutional investors own 57.11% of the company’s stock.

A number of equities analysts recently commented on FGEN shares. Mizuho reissued a “hold” rating and set a $61.00 price target on shares of FibroGen in a research note on Thursday, November 9th. ValuEngine lowered FibroGen from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. Finally, BidaskClub raised FibroGen from a “sell” rating to a “hold” rating in a research note on Thursday, December 21st. Four research analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $65.67.

In other news, CEO Thomas B. Neff sold 38,636 shares of the firm’s stock in a transaction that occurred on Thursday, December 21st. The stock was sold at an average price of $44.66, for a total value of $1,725,483.76. Following the completion of the sale, the chief executive officer now directly owns 3,022,934 shares of the company’s stock, valued at approximately $135,004,232.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Gerald Lema acquired 3,500 shares of the stock in a transaction dated Monday, December 4th. The stock was bought at an average cost of $46.70 per share, with a total value of $163,450.00. Following the completion of the purchase, the director now directly owns 3,500 shares in the company, valued at $163,450. The disclosure for this purchase can be found here. Insiders sold a total of 328,917 shares of company stock valued at $16,142,651 over the last ninety days. Corporate insiders own 13.60% of the company’s stock.

FibroGen Inc (NASDAQ FGEN) opened at $53.80 on Wednesday. FibroGen Inc has a one year low of $22.70 and a one year high of $63.00. The company has a debt-to-equity ratio of 0.16, a current ratio of 10.83 and a quick ratio of 10.83.

FibroGen (NASDAQ:FGEN) last posted its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by ($0.13). FibroGen had a negative net margin of 120.00% and a negative return on equity of 47.36%. research analysts predict that FibroGen Inc will post -1.75 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “FibroGen Inc (FGEN) Position Lessened by Omega Fund Management LLC” was originally published by Watch List News and is owned by of Watch List News. If you are reading this article on another site, it was copied illegally and republished in violation of US and international copyright & trademark laws. The correct version of this article can be read at https://www.watchlistnews.com/fibrogen-inc-fgen-position-lessened-by-omega-fund-management-llc/1850942.html.

FibroGen Company Profile

FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.

Want to see what other hedge funds are holding FGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for FibroGen Inc (NASDAQ:FGEN).

Institutional Ownership by Quarter for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.